BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout

After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers Squibb’s Cobenfy appear set to arrive later this year.